News
- ContagionLive: Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
- Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
Contact
BlueWillow Biologics, Inc.
2311 Green Rd. Suite A
Ann Arbor, MI 48105
734-302-4000
734-302-9150 fax
ContagionLive: Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
CEO Chad Costley, MD, MBA, provided an update with Sophia Abene from ContagionLive on BlueWillow Biologics’ NanoVax® intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness.
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
Ganesan S, Acosta H, Brigolin C, Orange K, Trabbic K, et al. (2022) Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. PLOS ONE. 2022 Nov 2;17(11): e0272594. Read online at PLOS ONE »
BlueWillow Announces Promising Results for Intranasal Covid-19 Booster Vaccine
BlueWillow’s intranasal vaccine candidate not only provides mucosal protection but also boosts the systemic immunity elicited from intramuscular vaccination against COVID-19. https://www.businesswire.com/news/home/20220302005134/en/BlueWillow-Biologics-and-Medigen-Vaccine-Biologics-Announce-Positive-Results-for-Intranasal-COVID-19-Booster-Candidate-in-Pre-clinical-Studies
BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARDA
ANN ARBOR, Mich.–(BUSINESS WIRE)–BlueWillow Biologics, Inc. today announced that the company will present positive interim data from its phase 1 clinical trial of a novel intranasal anthrax vaccine at a Lightning Talks Session of BARDA’s Industry Day, November 3 and 4, 2021. BlueWillow’s rPA/NE01 anthrax vaccine, BW-1010, developed in collaboration with Porton Biopharma Limited (UK) and […]
BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company’s Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs.
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the immune system via the nasal mucosa, with Porton […]
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
Research indicates that intranasal administration is effective at stimulating the mucosal immunity response. Preclinical study shows positive serum and mucosal immune response. Tapei, Taiwan & ANN ARBOR, Michigan, November 10, 2020 – Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, […]
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
BlueWillow Biologics today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for the company’s next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment in late 2019.
BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut Allergy Vaccine
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, has been awarded a Fast Track Small Business Research Innovation contract from the National Institute of Allergy and Infectious Diseases for development of an intranasal therapeutic peanut allergy vaccine.
BlueWillow Biologics Named to Crain’s ‘Cool Places to Work in Michigan’
BlueWillow Biologics® today announced the company has been recognized as one of the 2019 “Cool Places to Work in Michigan” by Crain’s Detroit.
BlueWillow Biologics Awarded Patent for Intranasal Genital Herpes Vaccine
BlueWillow Biologics® today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax® herpes simplex virus (HSV) vaccine.
BlueWillow Biologics Announces Issuance of Intranasal Anthrax Vaccine Patent
BlueWillow Biologics® today announced the issuance of U.S. patent number 10,138,279 covering an intranasal NanoVax® anthrax vaccine.
BlueWillow Biologics Awarded Grant for Chlamydia Vaccine Development
BlueWillow Biologics® today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax® vaccine for the prevention of chlamydia.
BlueWillow Biologics Announces Issuance of Therapeutic Cancer Vaccine Patent
BlueWillow announces the issuance of a patent to the University of Michigan, under exclusive license to BlueWillow, which allows use of BlueWillow’s NanoVax® platform with tumor antigens to create novel therapeutic vaccines that could potentially generate immune responses to treat existing cancers.